AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31579326
Drug: Ultrasound-guided rectus
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided rectus sheath block with 0.25% ropivacaine (0.5 ml/kg per side)
Trial: 31579326
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infiltration of the surgical field with 0.5% ropivacaine (0.4 ml/kg)
Trial: 25467200
Drug: Combined lumbopelvic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined lumbopelvic motor control and progressive hip strengthening exercise therapy programme
Trial: 19196472
Drug: PolyGlycoplex (PGX)
RxNorm normalized name: polyglycolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PolyGlycoplex (PGX) supplementation at a maximum dose of 10 g per day for 21 days
Trial: 11206864
Drug: Rizatriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (5 mg)
Trial: 3095111
Drug: Verapamil 3
RxNorm normalized name: verapamil 300 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 3 X 40 mg X d‐1
Trial: 3095111
Drug: Verapamil 3
RxNorm normalized name: verapamil 300 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 3 X 80 mg X d‐1
Trial: 3095111
Drug: Verapamil 3
RxNorm normalized name: verapamil 300 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 3 X 120 mg X d‐1
Trial: 27379911
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation (5 mg salbutamol sulfate, 1 mL saline + 1 mL salbutamol, nebulized for 10 minutes)
Trial: 27379911
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation (2 mL nebulized normal saline)
Trial: 22436797
Drug: Risperidone 0.5
RxNorm normalized name: risperidone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.5 mg every 12 hours (n = 51)
Trial: 20513750
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy titration to maximal tolerated dose
Trial: 18791928
Drug: AHCC (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHCC (3.0 g/day for 4 weeks)
Trial: 15908270
Drug: Mannitol infusion
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol infusion
Trial: 12050274
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg/d)
Trial: 1306421
Drug: Celaskon effervescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celaskon effervescens Spofa at a dose of 500 mg/day/person
Trial: 21566200
Drug: CS‐0777 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 0.1 mg
Trial: 21566200
Drug: CS‐0777 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 0.3 mg
Trial: 21566200
Drug: CS‐0777 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 1.0 mg
Trial: 21566200
Drug: CS‐0777 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 2.5 mg
Trial: 21566200
Drug: CS‐0777 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 (all doses)
Trial: 21566200
Drug: CS‐0777 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐0777 (2.5 mg)
Trial: 1522839
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of ethinyl estradiol and 1 mg of norgestrel (standard therapy)
Trial: 6398430
Drug: Desferrioxamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (30 mg/kg body weight/day for 1 week every 3 months)
Trial: 6398430
Drug: Hydroxychloroquine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (200 mg twice/wk orally)
Trial: 21883097
Drug: Perampanel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (up to 4 mg/day, dosed once- or twice-daily) in study 206
Trial: 21883097
Drug: Perampanel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (up to 12 mg/day, once-daily) in study 208
Trial: 18156659
Drug: Protein enriched
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein enriched recovery feeding (218 g protein, 435 g carbohydrate, 79 g fat)
Trial: 18156659
Drug: Isocaloric control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric control (34 g protein, 640 g carbohydrate, 79 g fat)
Trial: 11898004
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone acetate ointment
Trial: 11898004
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment and 0.1% tacrolimus ointment
Trial: 11898004
Drug: Tacrolimus treatment
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus treatment groups
Trial: 10202314
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI) with spacer and 1,000 microg salbutamol
Trial: 2157469
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg t.i.d. for six weeks
Trial: 7288605
Drug: Naloxone (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.2, 0.4 and 0.8 mg)
Trial: 7288605
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 and 10 mg)
Trial: 27093204
Drug: MMC Hydrogel
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC Hydrogel (0.8 mg MMC with 1cc water and propylene glycol)
Trial: 24361227
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and gemcitabine (PG) chemotherapy
Trial: 15241758
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy for the paretic upper limb (sensorimotor active‐assistive exercise or progressive‐resistive training)
Trial: 9696215
Drug: No bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bromocriptine treatment (Control)
Trial: 7808246
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (6 g.d-1)
Trial: 7808246
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration (2000 units 15 min prior to exercise)
Trial: 938185
Drug: Drug plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug plus psychotherapy
Trial: 938185
Drug: Milieu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milieu therapy
Trial: 28582809
Drug: Galacto-oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-oligosaccharides (GOS) 1.0 g twice a day for 12 weeks
Trial: 23388530
Drug: Inderal (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal (10 mg a day for 10‐20 minutes before meals) and Rozaliak cream (2 times a day)
Trial: 23388530
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a full comprehensive treatment complex including short courses of antibiotics, systemic metronidazole, antihistamines, desensitizing agents, traditional external therapy (Rosamet, 0.75% metronidazole cream)
Trial: 23388530
Drug: Inderal and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal and Rozaliak cream
Trial: 19388883
Drug: Arm-crank exercise
RxNorm normalized name: crack willow pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm-crank exercise training (twice weekly for 12 weeks)
Trial: 15549277
Drug: Carisoprodol (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisoprodol (700 mg)
Trial: 11544435
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (3.4 g/day)
Trial: 8316658
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose radiotherapy (LD‐RT) of 5 x 2 Gy (arm A: 32 patients)
Trial: 8316658
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose radiotherapy (HD‐RT) of either 10 x 2 Gy (arm B1; 8 patients) or 5 x 3.5 Gy (arm B2; 20 patients)
Trial: 3593901
Drug: Felodipine 15
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 15 mg
Trial: 3593901
Drug: Felodipine 40
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 40 mg
Trial: 3593901
Drug: Felodipine 1
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 1 mg (IV)
Trial: 3593901
Drug: Felodipine 3
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 3 mg (IV)
Trial: 24828850
Drug: PVB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB group (20 mL of 0.5% bupivacaine in the T9‐10 paravertebral space)
Trial: 22397953
Drug: tocilizumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tocilizumab (4 or 8 mg/kg)
Trial: 16685051
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 10 mg tablets twice a day during hospitalization
Trial: 9301400
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 60 mg kg‐1
Trial: 8419695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no immunomodulatory therapy)
Trial: 2943311
Drug: Spironolactone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (200 mg daily)
Trial: 30497077
Drug: Classical Turkish
RxNorm normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical Turkish music therapy
Trial: 26694904
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity shock wave treatment (12 sessions of 1,500 pulses of 0.09 mJ/mm(2) at 120 shock waves per minute)
Trial: 26694904
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity shock wave treatment
Trial: 26694904
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity shock wave treatment after sham treatment
Trial: 25223173
Drug: GnRHa 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa 3.6 mg by subcutaneous injection starting from the 1st day to the 5th day of menstruation, once per 28 days (Observation 1 group)
Trial: 25223173
Drug: GnRHa 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa 3.6 mg by subcutaneous injection in combination with Wenshen Xiaozheng Decoction (WXD) starting from the 1st day to the 5th day of menstruation, once per 28 days, plus WXD for 7 doses, one cycle per every 28 days (Observation 2 group)
Trial: 20578384
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Tiapride tablets)
Trial: 17672075
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and low-dose ASA
Trial: 9825249
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate maintenance therapy
Trial: 2553326
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition (0.18 g of N + 125 kJ day‐1 kg‐1) for 3 or 7 days before laparotomy
Trial: 30415141
Drug: Information package
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information package (brochure, video, personalized phone call reminder) delivered through home visits by specially trained agents
Trial: 19444280
Drug: High-dose ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ARB monotherapy (olmesartan medoxomil at 40 mg day(-1))
Trial: 19444280
Drug: ARB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB plus CCB combination therapy (20 mg day(-1) olmesartan with amlodipine or azelnidipine)
Trial: 16762125
Drug: Hawthorn extract
RxNorm normalized name: hawthorn extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hawthorn extract (1200 mg daily)
Trial: 15628632
Drug: Electrotherapy (high-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrotherapy (high-frequency transcutaneous and intranasal electric stimulation of nasal muscles for 15 minutes, 3 times a week for 10 weeks)
Trial: 9457607
Drug: Vancomycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (5 mg/kg, twice daily, 1 h infusions)
Trial: 3074614
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg before sleeping)
Trial: 3074614
Drug: Betahistine dichlorhydrate
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine dichlorhydrate (8 mg 3 times daily)
Trial: 28019091
Drug: Nivolumab (0.3-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (0.3-10.0 mg/kg)
Trial: 25852210
Drug: Composite score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite score of thrombolytic factors (fibrinogen, active and total plasminogen activator inhibitor [PAI]-1)
Trial: 25852210
Drug: Composite score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite score of cytokines/adipokines (tumor necrosis factor receptor-1 and -2, active and total PAI-1, IL-6)
Trial: 19351624
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infliximab every 8 weeks (arm A)
Trial: 19351624
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab every 8 weeks (arm B)
Trial: 16719029
Drug: Daily multinutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multinutrient energy‐dense oral supplement (6.3 kJ/mL) for six weeks
Trial: 16719029
Drug: Tri‐weekly resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri‐weekly resistance training for 12 weeks
Trial: 16719029
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (nutrition and resistance training)
Trial: 12709775
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg/day followed by 400 mg/day)
Trial: 12709775
Drug: Modafinil using
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil using a taper-down/titrate-up protocol
Trial: 8361609
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg quinapril (1 x 20 mg tablet per day)
Trial: 8361609
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of nifedipine retard tablets (1 x 20 mg tablet twice daily)
Trial: 3740675
Drug: Any alkylating
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any alkylating agent
Trial: 27270480
Drug: NA mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA mFOLFOX6 chemotherapy alone (CS group, n = 48)
Trial: 27270480
Drug: NA mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54)
Trial: 12895689
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (120 mg/day, n=15)
Trial: 31266155
Drug: OLE (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLE (50 mg oleuropein) consumed in capsule form 3 times a day for 1 week
Trial: 21736770
Drug: Casein cross-linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein cross-linked with transglutaminase (Cas-TG, rigid gel)
Trial: 16534456
Drug: 0.9% unpreserved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% unpreserved unit-dose saline (control)
Trial: 12723527
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (n = 17)
Trial: 27418381
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus medication (venlafaxine plus lithium, four continuation ECT treatments over 1 month)
Trial: 27418381
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only (venlafaxine plus lithium over 24 weeks)
Trial: 27418381
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus medication
Trial: 22310055
Drug: 3 or
RxNorm normalized name: Cytra-3 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 6 months of neo‐adjuvant androgen deprivation therapy (NADT)
Trial: 20040034
Drug: Silica coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silica coating and silanization (n = 8 for each taper angle)
Trial: 20040034
Drug: HF acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF acid etching and silanization (n = 8 for each taper angle)
Trial: 15801991
Drug: Cerivastatin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.2 mg-0.8 mg) at 6 weeks
Trial: 15801991
Drug: Cerivastatin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.2 mg-0.8 mg) at 12 weeks
Trial: 15801991
Drug: Cerivastatin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.2 mg-0.8 mg) over three time points
Trial: 12464951
Drug: Intranasal amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal amphotericin B (20 mL of a 100 microg/mL solution twice daily)
Trial: 22671949
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (traditional didactic teaching and drug refusal skills)
Trial: 20642555
Drug: Woohwangcheongsimwon suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Woohwangcheongsimwon suspension
Trial: 15080766
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 4 days plus lumiracoxib 400 mg
Trial: 15080766
Drug: Aluminium hydroxide/magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide/magnesium hydroxide antacid plus lumiracoxib 400 mg
Trial: 15080766
Drug: Lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 400 mg alone
Trial: 8074020
Drug: Molsidomine infusion
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine infusion
Trial: 2552552
Drug: Fragmin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin administered subcutaneously twice daily (initial dose 100 U anti‐Xa/kg/12 h, adjusted based on anti‐Xa activity)
Trial: 2552552
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin administered by continuous infusion (initial dose 240 UI/kg/12 h, adjusted based on APTT)
Trial: 25719937
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide implant (FAI)
Trial: 24356595
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy during the DCCT
Trial: 21352112
Drug: OPUS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPUS treatment (assertive community treatment with family involvement and social skills training)
Trial: 21352112
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (contact with a community mental health centre)
Trial: 12375299
Drug: New antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antidepressant (dose escalation)
Trial: 8665883
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg
Trial: 94225
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 5% lidocaine and 5% prilocaine
Trial: 94225
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 5% lidocaine and 5% prilocaine used daily for 3-4 weeks
Trial: 27423432
Drug: Quercetin (162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (162 mg/d)